Bacteriophage Therapy of Bacterial Infections: The Rediscovered Frontier

Basit Öğe Kaydı
dc.authoridSessevmez, Melike/0000-0002-6233-9574
dc.authoridDuzgunes, Nejat/0000-0001-6159-1391
dc.contributor.authorDuzgunes, Nejat
dc.contributor.authorSessevmez, Melike
dc.contributor.authorYildirim, Metin
dc.date.accessioned2025-03-17T12:25:13Z
dc.date.available2025-03-17T12:25:13Z
dc.date.issued2021
dc.departmentTarsus Üniversitesi
dc.description.abstractAntibiotic-resistant infections present a serious health concern worldwide. It is estimated that there are 2.8 million antibiotic-resistant infections and 35,000 deaths in the United States every year. Such microorganisms include Acinetobacter, Enterobacterioceae, Pseudomonas, Staphylococcus and Mycobacterium. Alternative treatment methods are, thus, necessary to treat such infections. Bacteriophages are viruses of bacteria. In a lytic infection, the newly formed phage particles lyse the bacterium and continue to infect other bacteria. In the early 20th century, d'Herelle, Bruynoghe and Maisin used bacterium-specific phages to treat bacterial infections. Bacteriophages are being identified, purified and developed as pharmaceutically acceptable macromolecular drugs, undergoing strict quality control. Phages can be applied topically or delivered by inhalation, orally or parenterally. Some of the major drug-resistant infections that are potential targets of pharmaceutically prepared phages are Pseudomonas aeruginosa, Mycobacterium tuberculosis and Acinetobacter baumannii.
dc.identifier.doi10.3390/ph14010034
dc.identifier.issn1424-8247
dc.identifier.issue1
dc.identifier.pmid33466546
dc.identifier.scopus2-s2.0-85099380246
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.3390/ph14010034
dc.identifier.urihttps://hdl.handle.net/20.500.13099/1565
dc.identifier.volume14
dc.identifier.wosWOS:000610690000001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMdpi
dc.relation.ispartofPharmaceuticals
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250316
dc.subjectlytic infection
dc.subjectantibiotic-resistance
dc.subjectMycobacterium tuberculosis
dc.subjectAcinetobacter baumannii
dc.subjectPseudomonas aeruginosa
dc.subjectphage production
dc.subjectmagistral phage
dc.subjectpulmonary delivery
dc.subjectoral administration
dc.subjecttopical delivery
dc.titleBacteriophage Therapy of Bacterial Infections: The Rediscovered Frontier
dc.typeReview

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu